Unexplained weight loss (UWL), defined as a decrease in body weight of 5% or more within a six-month period without a clear cause, is a common yet challenging clinical scenario. It may be an indicator of underlying serious conditions, both malignant and non-malignant, warranting a comprehensive evaluation.
The initial approach to evaluating UWL should include a detailed history and physical examination. The history should focus on dietary intake, physical activity, changes in taste or smell, psychiatric symptoms, and other systemic symptoms. The physical examination should aim at identifying signs of chronic diseases, malignancies, or malnutrition.
Initial laboratory tests should include complete blood count, metabolic panel, thyroid function tests, and inflammatory markers. The role of imaging studies is not well-defined in the absence of specific symptoms or signs, but computed tomography (CT) of the abdomen and pelvis may be considered in certain cases.
Special populations may require additional investigations. In the elderly, cognitive impairment and social factors may contribute to UWL. In patients with HIV, UWL may be a sign of uncontrolled disease or opportunistic infections. In these cases, a tailored approach may be necessary.
Management should be directed at the underlying cause, if identified. In cases where no clear cause is found, symptomatic and nutritional support should be provided. A close follow-up is essential to monitor for new symptoms or signs that may point to a specific diagnosis.
Unexplained weight loss is a complex clinical issue that requires a systematic and comprehensive approach. While it can be a sign of serious underlying conditions, a thorough evaluation often leads to the identification of treatable causes. Continued research into this area is needed to further refine our approach and improve patient outcomes.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation